US EditionPANTHERx® Rare Introduces New Capabilities to Support Cell and Gene Therapies
- PANTHERx Rare launched RxARECONCIERGE in Pittsburgh on April 2, 2025, a new patient support model.
- PANTHERx developed RxARECONCIERGE to address the unique needs of cell and gene therapies.
- RxARECONCIERGE improves access, logistics, and care coordination for cell and gene therapy patients.
- PANTHERx CEO Bansi Nagji stated the expansion to cell and gene therapy was a natural step.
- PANTHERx, known as The Rare Disease Pharmacy, is dual-accredited and licensed in all 50 states.
24 Articles
24 Articles
LoudounTimes.com
PANTHERx® Rare Introduces New Capabilities to Support Cell and Gene Therapies
PITTSBURGH, April 2, 2025 /PRNewswire/ -- PANTHERx® Rare, a leader in rare disease product patient access and support services in the United States, is pleased to announce the launch of RxARECONCIERGE™, a new patient support model to improve access, logistics,…
In Leipzig, researchers talk about progress in modern therapies with genetically modified viruses. Although these approaches are expensive, they can now cure life-long diseases with a unique gift.
AscellaHealth Launches Specialty & Rare Pipeline Digest to Guide Pharmaceutical Stakeholders
BERWYN, PA — AscellaHealth has introduced its latest Specialty & Rare Pipeline Digest™, a quarterly publication designed to provide stakeholders with comprehensive insights into current and upcoming specialty and rare disease drug developments. The digital resource focuses on new drug launches, regulatory approvals, and advancements in biosimilars, as well as cell and gene therapies (CGTs). The initiative supports stakeholders navigating the dyn…
Coverage Details
Bias Distribution
- 67% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
